#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	17260	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2641	807.4	1	SNP	n	C1184T	0	.	.	1184	1184	C	1711	1711	C	1054	C,T,A	1052,1,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29634	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4047	913.2	0	.	n	.	0	T695C	SNP	695	695	T	1268	1268	C	1158	C,T,A	1156,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29634	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4047	913.2	0	.	n	.	0	G1337A	SNP	1337	1337	G	1910	1910	A	1270	A,C,G	1266,3,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29634	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4047	913.2	0	.	n	.	0	T1971C	SNP	1971	1971	T	2544	2544	C	1024	C,A,G	1021,2,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29634	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4047	913.2	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	3170	3170	T	1031	T,G	1029,2	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29634	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4047	913.2	1	SNP	n	A2045G	0	.	.	2045	2045	A	2618	2618	A	921	A,C	919,2	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	2676	folP	852	852	100.0	folP.l15.c4.ctg.1	1988	167.9	1	SNP	p	R228S	1	.	.	682	684	AGC	1229	1231	AGC	274;272;273	A,T,C;G;C,A	272,1,1;272;272,1	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	6610	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3851	213.5	1	SNP	p	S91F	0	.	.	271	273	TCC	712	714	TCC	246;243;245	T;C;C	246;243;245	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	6610	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3851	213.5	1	SNP	p	D95N	0	.	.	283	285	GAC	724	726	GAC	244;246;247	G;A;C,A	244;246;246,1	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	6610	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3851	213.5	1	SNP	p	D95G	0	.	.	283	285	GAC	724	726	GAC	244;246;247	G;A;C,A	244;246;246,1	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_W_01449	mtrR.WHO_W_01449	1	1	27	2438	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1793	169.3	1	SNP	p	G45D	1	.	.	133	135	GAC	677	679	GAC	279;279;279	G;A;C,T	279;279;278,1	mtrR.WHO_W_01449:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	1342	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c4.ctg.1	1409	118.7	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	6142	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3342	228.7	1	SNP	p	D86N	0	.	.	256	258	GAC	767	769	GAC	252;250;252	G,T;A,C,G;C	251,1;247,2,1;252	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	6142	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3342	228.7	1	SNP	p	S87R	0	.	.	259	261	AGT	770	772	AGT	254;251;248	A;G;T	254;251;248	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	6142	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3342	228.7	1	SNP	p	S87W	0	.	.	259	261	AGT	770	772	AGT	254;251;248	A;G;T	254;251;248	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	6142	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3342	228.7	1	SNP	p	S87I	0	.	.	259	261	AGT	770	772	AGT	254;251;248	A;G;T	254;251;248	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	6142	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3342	228.7	1	SNP	p	S88P	0	.	.	262	264	TCC	773	775	TCC	250;250;249	T;C;CG,C	250;250;244,1	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	5108	parE	1986	1986	100.0	parE.l15.c4.ctg.1	3213	198.3	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1902	1904	GGC	285;285;284	G;G,T;C	285;284,1;284	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	4914	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2946	207.8	1	SNP	p	A311V	0	.	.	931	933	GCA	1410	1412	GCA	293;292;291	G;C;A	293;292;291	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4914	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2946	207.8	1	SNP	p	I312M	0	.	.	934	936	ATC	1413	1415	ATC	290;291;292	A;T,G;C,A,T	290;290,1;290,1,1	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4914	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2946	207.8	1	SNP	p	V316P	0	.	.	946	948	GTG	1425	1427	GTG	285;286;287	G,A;T;G,A	284,1;286;286,1	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4914	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2946	207.8	1	SNP	p	V316T	0	.	.	946	948	GTG	1425	1427	GTG	285;286;287	G,A;T;G,A	284,1;286;286,1	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4914	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2946	207.8	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1929	1931	ACC	247;246;244	A;C;C,A	247;246;243,1	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4914	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2946	207.8	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1983	1985	GCG	250;252;254	G,T;C,G;G,A	249,1;250,2;253,1	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4914	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2946	207.8	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1983	1985	GCG	250;252;254	G,T;C,G;G,A	249,1;250,2;253,1	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4914	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2946	207.8	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2106	2108	GGC	277;278;281	G;G;C,A	277;278;280,1	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4914	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2946	207.8	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2115	2117	GGC	278;282;286	G,A;G;C	277,1;282;286	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4914	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2946	207.8	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2133	2135	CCG	289;290;292	C,G,T;C;G,T,A	286,2,1;290;289,1,1	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	27	6468	ponA	2397	2397	99.96	ponA.l6.c17.ctg.1	3541	227.7	1	SNP	p	L421P	0	.	.	1261	1263	CTG	1885	1887	CTG	253;255;254	C;T;G	253;255;254	ponA.WHO_F_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	3186	porA	1146	1146	99.83	porA.l15.c4.ctg.1	2349	169.2	0	.	p	.	0	M83fs	FSHIFT	247	247	A	874	874	C	250	C	250	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	354	porB1a	984	271	91.51	porB1a.l6.c30.ctg.2	443	30.3	0	.	p	.	0	S271T	NONSYN	811	813	TCG	108	110	ACT	75;75;75	A;C;T	75;75;75	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	354	porB1a	984	271	91.51	porB1a.l6.c30.ctg.2	443	30.3	0	.	p	.	0	Y273D	NONSYN	817	819	TAT	114	116	GAT	75;75;75	G;A,C;T	75;74,1;75	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	354	porB1a	984	271	91.51	porB1a.l6.c30.ctg.2	443	30.3	0	.	p	.	0	D274S	NONSYN	820	822	GAT	117	119	AGT	75;75;75	A;G;T	75;75;75	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	354	porB1a	984	271	91.51	porB1a.l6.c30.ctg.2	443	30.3	0	.	p	.	0	N277H	NONSYN	829	831	AAC	126	128	CAC	73;73;73	C;A;C	73;73;73	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	354	porB1a	984	271	91.51	porB1a.l6.c30.ctg.2	443	30.3	0	.	p	.	0	R307E	NONSYN	919	921	AGA	216	218	GAA	1;1;1	G;A;A	1;1;1	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	354	porB1a	984	271	91.51	porB1a.l6.c30.ctg.2	443	30.3	0	.	p	.	0	T311A	NONSYN	931	933	ACA	228	230	GCA	1;1;1	G;C;A	1;1;1	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	354	porB1a	984	271	91.51	porB1a.l6.c30.ctg.2	443	30.3	0	.	p	.	0	E312D	NONSYN	934	936	GAA	231	233	GAC	1;1;1	G;A;C	1;1;1	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	354	porB1a	984	271	91.51	porB1a.l6.c30.ctg.2	443	30.3	0	.	p	.	0	F314I	NONSYN	940	942	TTC	237	239	ATC	1;1;1	A;T;C	1;1;1	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	354	porB1a	984	271	91.51	porB1a.l6.c30.ctg.2	443	30.3	0	.	p	.	0	A316S	NONSYN	946	948	GCG	243	245	TCG	1;1;1	T;C;G	1;1;1	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	354	porB1a	984	271	91.51	porB1a.l6.c30.ctg.2	443	30.3	0	.	p	.	0	V318A	NONSYN	952	954	GTC	249	251	GCC	1;1;1	G;C;C	1;1;1	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	354	porB1a	984	271	91.51	porB1a.l6.c30.ctg.2	443	30.3	0	.	p	.	0	G319S	NONSYN	955	957	GGC	252	254	AGC	1;1;1	A;G;C	1;1;1	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	354	porB1a	984	271	91.51	porB1a.l6.c30.ctg.2	443	30.3	0	.	p	.	0	G320A	NONSYN	958	960	GGT	255	257	GCC	1;1;1	G;C;C	1;1;1	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	354	porB1a	984	271	91.51	porB1a.l6.c30.ctg.2	443	30.3	0	.	p	.	0	G322V	NONSYN	964	966	GGT	261	263	GTT	1;1;1	G;T;T	1;1;1	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	3212	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1600	243.0	0	.	p	.	0	G38E	NONSYN	112	114	GGA	524	526	GAA	285;286;286	G;A,T;A	285;285,1;286	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	3212	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1600	243.0	0	.	p	.	0	E48G	NONSYN	142	144	GAA	554	556	GGA	284;287;285	G;G;A,C	283;286;283,2	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	3212	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1600	243.0	0	.	p	.	0	T87A	NONSYN	259	261	ACT	671	673	GCT	268;270;270	G;C;T	268;270;270	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	3212	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1600	243.0	0	.	p	.	0	T89S	NONSYN	265	267	ACC	677	679	AGC	259;256;255	A,C;G;C	258,1;256;255	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	3212	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1600	243.0	0	.	p	.	0	.	MULTIPLE	358	359	AA	769	770	CG	210;208	C;G	210;207	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	3212	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1600	243.0	0	.	p	.	0	.	MULTIPLE	361	362	GA	772	774	CAG	209;211;215	C;A;G	209;211;215	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	3212	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1600	243.0	0	.	p	.	0	N122K	NONSYN	364	366	AAC	776	778	AAA	217;219;223	A;A;A,C	217;219;222,1	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	3212	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1600	243.0	0	.	p	.	0	K143E	NONSYN	427	429	AAA	839	841	GAA	278;280;283	G,T,C;A;A	275,2,1;280;283	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	3212	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1600	243.0	0	.	p	.	0	V151A	NONSYN	451	453	GTA	863	865	GCA	298;300;300	G,C;C;A	297,1;300;300	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	3212	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1600	243.0	0	.	p	.	0	N212D	NONSYN	634	636	AAT	1046	1048	GAT	290;289;287	G;A;T	290;289;286	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	3212	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1600	243.0	0	.	p	.	0	D213G	NONSYN	637	639	GAT	1049	1051	GGT	287;284;283	G;G;T	287;284;283	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	3212	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1600	243.0	0	.	p	.	0	I218M	NONSYN	652	654	ATA	1064	1066	ATG	273;271;267	A;T,A;G	273;270,1;267	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	3212	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1600	243.0	0	.	p	.	0	T256A	NONSYN	766	768	ACA	1178	1180	GCA	260;259;259	G;C;A	260;259;259	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	3212	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1600	243.0	0	.	p	.	0	W257T	NONSYN	769	771	TGG	1181	1183	ACG	256;255;255	A;C;G,T	256;255;253,2	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	3212	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1600	243.0	0	.	p	.	0	R258G	NONSYN	772	774	CGT	1184	1186	GGG	259;260;260	G;G;G,T	259;260;259,1	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	3212	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1600	243.0	0	.	p	.	0	A259V	NONSYN	775	777	GCT	1187	1189	GTT	260;260;258	G;T,A;T	260;259,1;258	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	3212	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1600	243.0	0	.	p	.	0	L279V	NONSYN	835	837	TTA	1247	1249	GTA	280;279;278	G;T;A	280;279;278	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	3212	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1600	243.0	0	.	p	.	0	S292T	NONSYN	874	876	TCT	1286	1288	ACT	278;277;275	A;C,T;T	278;276,1;275	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	3212	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1600	243.0	0	.	p	.	0	H294D	NONSYN	880	882	CAT	1292	1294	GAT	286;288;289	G;A,C;T	286;286,2;289	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	3212	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1600	243.0	0	.	p	.	0	Y298H	NONSYN	892	894	TAC	1304	1306	CAC	304;305;310	C,T;A;C	303,1;305;310	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	3212	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1600	243.0	1	SNP	p	G120K	1	.	.	358	360	AAG	769	771	CGG	210;208;209	C;G;G,A	210;207;208,1	porB1b.WHO_Z_02266c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	3212	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1600	243.0	1	SNP	p	D121N	0	.	.	361	363	GAC	772	775	CGC	209;215;218	C;G;C	209;215;218	porB1b.WHO_Z_02266c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	3212	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1600	243.0	1	SNP	p	A121D	1	.	.	361	363	GAC	772	775	CGC	209;215;218	C;G;C	209;215;218	porB1b.WHO_Z_02266c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	11654	rpoB	4179	4179	100.0	rpoB.l15.c17.ctg.1	5320	273.4	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2272	2274	AAT	325;323;323	A,C;A,C;T,G	324,1;322,1;322,1	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1562	rpsJ	312	312	100.0	rpsJ.l6.c4.ctg.1	1319	147.4	1	SNP	p	V57M	1	.	.	169	171	ATG	699	701	ATG	300;299;296	A;T;G,C	300;299;295,1	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
